实用心脑肺血管病杂志
實用心腦肺血管病雜誌
실용심뇌폐혈관병잡지
PRACTICAL JOURNAL OF CARDIAC CEREBRAL PNEUMAL AND VASCULAR DISEASE
2014年
9期
51-51,52
,共2页
冠心病%高脂血症%阿托伐他汀%治疗结果
冠心病%高脂血癥%阿託伐他汀%治療結果
관심병%고지혈증%아탁벌타정%치료결과
Coronary disease%Hyperlipidemia%Atorvastatin%Treatment outcome
目的：观察不同剂量阿托伐他汀治疗冠心病伴高脂血症的临床疗效。方法选择2010年4月-2011年4月我院收治的冠心病伴高脂血症患者50例，将其随机分为对照组和观察组，各25例。对照组患者给予阿托伐他汀15 mg/ d 进行治疗，观察组患者给予阿托伐他汀30 mg/ d 进行治疗，疗程均为2个月。测定治疗前后两组患者 TC、LDL - C 及 HDL - C 水平变化，观察治疗期间不良反应情况。结果治疗前两组患者 TC、HDL - C 及 LDL - C 水平比较，差异均无统计学意义（P ﹥0.05）；治疗后观察组患者 TC 和 LDL - C 水平低于对照组（P ﹤0.05）。治疗期间观察组不良反应发生率为28%，低于对照组的52%（P ﹤0.05）。结论阿托伐他汀30 mg/ d 对冠心病伴高脂血症患者降脂效果优于阿托伐他汀15 mg/ d，且不良反应少。
目的：觀察不同劑量阿託伐他汀治療冠心病伴高脂血癥的臨床療效。方法選擇2010年4月-2011年4月我院收治的冠心病伴高脂血癥患者50例，將其隨機分為對照組和觀察組，各25例。對照組患者給予阿託伐他汀15 mg/ d 進行治療，觀察組患者給予阿託伐他汀30 mg/ d 進行治療，療程均為2箇月。測定治療前後兩組患者 TC、LDL - C 及 HDL - C 水平變化，觀察治療期間不良反應情況。結果治療前兩組患者 TC、HDL - C 及 LDL - C 水平比較，差異均無統計學意義（P ﹥0.05）；治療後觀察組患者 TC 和 LDL - C 水平低于對照組（P ﹤0.05）。治療期間觀察組不良反應髮生率為28%，低于對照組的52%（P ﹤0.05）。結論阿託伐他汀30 mg/ d 對冠心病伴高脂血癥患者降脂效果優于阿託伐他汀15 mg/ d，且不良反應少。
목적：관찰불동제량아탁벌타정치료관심병반고지혈증적림상료효。방법선택2010년4월-2011년4월아원수치적관심병반고지혈증환자50례，장기수궤분위대조조화관찰조，각25례。대조조환자급여아탁벌타정15 mg/ d 진행치료，관찰조환자급여아탁벌타정30 mg/ d 진행치료，료정균위2개월。측정치료전후량조환자 TC、LDL - C 급 HDL - C 수평변화，관찰치료기간불량반응정황。결과치료전량조환자 TC、HDL - C 급 LDL - C 수평비교，차이균무통계학의의（P ﹥0.05）；치료후관찰조환자 TC 화 LDL - C 수평저우대조조（P ﹤0.05）。치료기간관찰조불량반응발생솔위28%，저우대조조적52%（P ﹤0.05）。결론아탁벌타정30 mg/ d 대관심병반고지혈증환자강지효과우우아탁벌타정15 mg/ d，차불량반응소。
Objective To observe the clinical effect of different doses of Atorvastatin on coronary heart disease and hy-perlipidemia. Methods From April 2010 to April 2011,50 patients with coronary heart disease and hyperlipidemia in our hos-pital were chosen,and they were randomly divided into control group and observation group,each of 25 cases. Control group giv-en Atorvastatin(15 mg/ d),observation group given Atorvastatin(30 mg/ d),both groups treated for two months. The levels of TC,LDL - C and HDL - C of the two groups were detected before and after treatment,the adverse reactions during treatment were observed. Results There was no significant differences of TC,HDL - C and LDL - C levels between the two groups before treatment(P ﹥ 0. 05);after treatment,the levels of TC and LDL - C of observation group were lower than those of control group (P ﹤ 0. 05). The incidence of adverse reactions of observation group was 28% ,was lower than that of control group of 52% (P﹤ 0. 05). Conclusion Atorvastatin(30 mg/ d)has a better lipid - lowering effect and fewer adverse reactions than Atorvasta-tin(15 mg/ d)on coronary heart disease and hyperlipidemia.
